FDA adds EV-durvalumab option for muscle-invasive bladder cancer
The FDA has approved neoadjuvant EV plus perioperative durvalumab for muscle-invasive bladder cancer, Tom Powles of Barts Cancer Institute said on X during Uromigos live. Powles said the nod rests on positive event-free and overall survival signals and gives patients another option alongside nine cycles of perioperative EVP.
- 2 sources report it: oncodaily.com, msn.com.
- The source published it on Nov 14, 2026 at 2:40 PM.
Nothing open. Every check passed.
Powles, head of solid tumor research at Barts Cancer Institute, announced the approval on X while Uromigos was live. He framed the decision as backing from a positive EFS and OS signal. The new option sits alongside nine cycles of perioperative EVP, which is already approved, he said.
The approval lands in muscle-invasive bladder cancer, where the VOLGA trial is testing perioperative immunotherapy and antibody-drug conjugate therapy. VOLGA, listed as NCT04960709, is a global randomized Phase III study. It targets patients who cannot take cisplatin-based chemotherapy or decline it.
The trial enrolled 695 adults with resectable MIBC who were scheduled for radical cystectomy, or bladder removal. Eligible disease was clinical stage T2-T4aN0/1M0 or T1N1M0. Participants were split 1:1:1 across three arms. The dual primary endpoints compare event-free survival for each experimental arm against the control arm; overall survival is a key secondary endpoint.
TopicsTom Powles · Barts Cancer Institute · FDA · durvalumab · EV · VOLGA trial · muscle-invasive bladder cancer · Uromigos
Written by AI from verified reporting. Not financial advice.

